Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -10.07
- Piotroski Score 1.00
- Grade Buy
- Symbol (KPTI)
- Company Karyopharm Therapeutics Inc.
- Price $0.89
- Changes Percentage (-4.77%)
- Change -$0.04
- Day Low $0.86
- Day High $0.93
- Year High $1.95
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $14.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.27
- Trailing P/E Ratio -0.76
- Forward P/E Ratio -0.76
- P/E Growth -0.76
- Net Income $-143,099,000
Income Statement
Quarterly
Annual
Latest News of KPTI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
Carolyn, the conference operator, welcomes participants to Karyopharm Therapeutics' Q2 2024 financial results call. Elhan Webb, Senior VP of Investor Relations, discusses financial updates. Reshma Ran...
By Yahoo! Finance | 2 months ago -
Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
The article discusses the stock market trends, economic conditions, and highlights Karyopharm Therapeutics Inc. as one of the best one-dollar stocks to buy. It explores the company's progress, potenti...
By Yahoo! Finance | 3 months ago
